Identification of phenotypes and endotypes by cluster analysis among patients with severe asthma in Japan

Conditions

Asthma

Suzukawa M, Ohta K, Hashimoto H, Oyamada Y, Miki M, Ogawara M, Inoue Y, Saito AM, Fukutomi Y, Kobayashi N, Taniguchi M, NHOM-Asthma Study Group.

2023-01-165 citations

10.1016/j.anai.2023.01.003

Classifications of moderate to severe asthma phenotypes in Japan and analysis of serum biomarkers: A Nationwide Cohort Study in Japan (NHOM Asthma Study).

Suzukawa M, Ohta K, Fukutomi Y, Hashimoto H, Endo T, Abe M, Kamide Y, Yoshida M, Kikuchi Y, Kita T, Chibana K, Tanimoto Y, Hyodo K, Takata S, Inui T, Yasui M, Harada Y, Sato T, Sakakibara Y, Minakata Y, Inoue Y, Tamaki S, Shinohara T, Takami K, Tsubakihara M, Oki M, Wakamatsu K, Horiba M, Ideura G, Hidaka K, Saito AM, Kobayashi N, Taniguchi M.

2022-07-028 citations

10.1016/j.alit.2022.06.002

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Asthma patients visiting study institutions. 2) Patients who developed asthma more than one year ago. 3) Age: patients aged 16 years or older at time of acquisition of informed consent. 4) Patients who provided written consents for this study by themselves. 5) With regard to "severe asthma patients", patients in the treatment step 3 or 4 in "Asthma Prevention and Management Guidelines 2015". (i.e., Treatment step 3: treatment with medium to high doses of inhaled corticosteroids plus any one or more from long-acting B2 stimulant, leukotriene receptor antagonist, theophylline and long-acting anticholinergic agent. Treatment step 4: treatment with high-dose inhaled corticosteroids plus two or more from long-acting B2 stimulant, leukotriene receptor antagonist, theophylline, long-acting muscarinic antagonist, anti-IgE antibodies and oral steroid.)

Exclusion criteria

Exclusion criteria: 1) Patients for whom the principal investigator or sub-investigators decided not suitable for participation in this study.

Design outcomes

Primary

Measure	Time frame
Phenotype classification in severe asthmatics	—

Secondary

Measure	Time frame
Actual clinical practice for asthma and its' control status Distribution of cluster-specific endotypes' distribution among patients with severe asthma	—

Countries

Japan

Contacts

Public ContactMaho Suzukawa

National Hospital Organization Tokyo National Hospital Clinical Research Center, Center for Pulmonary Diseases

suzukawam@tokyo-hosp.jp042-491-2111

Outcome results